《Current Hematologic Malignancy Reports》雜志的最新年發文量為34篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在血液學領域的學術影響力。
該刊聚焦于醫學-血液學領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 12周，或約稿 。
Current Hematologic Malignancy Reports 雜志發文統計
文章名稱引用次數
- Targeting BTK in CLL: Beyond Ibrutinib21
- CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease20
- Emerging EZH2 Inhibitors and Their Application in Lymphoma19
- Relapsed T Cell ALL: Current Approaches and New Directions12
- Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia11
- Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma11
- NK/T Cell Lymphoma: Updates in Therapy10
- Adult T Cell Leukemia-Lymphoma (ATL): State of the Art10
- Pathogenesis of Enteropathy-Associated T Cell Lymphoma10
- Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia9
國家/地區發文量
- USA149
- Australia5
- England5
- Italy4
- Canada3
- CHINA MAINLAND2
- GERMANY (FED REP GER)2
- Japan2
- France1
- Greece1
